IL17A and inflammatory bowel disease: Even if a matter of ongoing debate concerns the precise epithelial cell type that is targeted by IL-17 and IL-22, we and other postulated that the treatment of IBD may be improved with therapeutic agents that reinforce IL-17 and IL-22-mediated intestinal barrier function.